体内CAR-T这个概念，存在多年，一直未成熟，多用LNP或者慢病毒作为载体，在载体上表达靶向抗体，作为靶向结合定位转染。其中，EsoBiotec以其慢病毒载体的体内CAR-T走在前面，在早期IIT临床中展现了不错的效果。 2025年3月17日，阿斯利康达成最终协议，收购EsoBiotec，阿斯利康将以现金和无债务方式收购EsoBiotec，交易总额高达10亿美元。包括4.25亿美元首期付款，以及根 ...

When naive T cells encounter antigen-presenting cells (APCs), membrane and cytoplasmic molecules rearrange at the T cell–APC contact area to form the immune synapse. Finetti et al. now reveal an ...

截至2025年3月28日收盘，东北制药（000597）报收于5.21元，较上周的5.03元上涨3.58%。本周，东北制药3月28日盘中最高价报5.35元。3月24日盘中最低价报4.97元。东北制药当前最新总市值74.46亿元，在化学制药板块市值排名6 ...

T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

证券之星消息，2025年3月25日东北制药（000597）发布公告称公司于2025年3月25日接受机构调研，博时基金张之瑞参与。 具体内容如下： 问：北京鼎成肽源生物技术有限公司的主要产品有哪些，分别应用于哪些领域？

The posters will feature: 1) Clinical results for EMB-01, an EGFR x cMet bispecific antibody, in colorectal cancer; 2) Preclinical data for EM1031, a novel KLK2 x CD3 bispecific T-cell engager; 3) ...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell engagers (TCR-TCEs), the “off-the-shelf” immunotherapies for solid tumours.

“This co-development agreement further expands the application of Medigene’s TCRs into off-the-shelf TCR-guided modalities and underscores our commitment to forging value-driven partnerships ...